BioSpace News Archive

Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at Citi’s 16th Annual BioPharma Conference on Friday, September 10, 2021

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY ® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...

Biomerica Inc. (NASDAQ: BMRA) today announced it expects final patient enrollment in its endpoint clinical trial for its InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.

Stryker (NYSE:SYK) will participate in Morgan Stanley’s 19th Annual Global Healthcare Conference on Monday, September 13, 2021.

ABVC BioPharma, Inc. today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at: https://scr.zacks.com/news/news-details/2021/ABVC-Company-Continues-to-Advance-Lead-Assets--Earlier-Stage-Candidates-/default.aspx .

Alphatec Holdings, Inc., a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will participate in the following investor conferences

Agathos Biologics today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program.

Gemina Laboratories Ltd. (CSE:GLAB) (the “Company” or “Gemina”) is pleased to announce several key hires within our Research and Development team.

Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed a 21 per cent relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo

Physicians from four medical centers recently published data this month from an initial six patients implanted with CivaSheet® to treat retroperitoneal sarcoma.